Who we are
The Vaccitech Team
CEO & Board Director
Dr. Thomas G. Evans
Dr. Thomas G. Evans received his MD from the University of Virginia and trained in Internal Medicine at UCSF, and in Infectious Diseases back at Virginia. He established a laboratory during his first position at the University of Utah and directed the HIV clinic. He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. His academic research centered on leishmania and HIV vaccine development and led to him joining Vical, a DNA vaccine developer as Chief Medical Officer in 2002. In 2005 he joined the Novartis Institutes for Biomedical Research as Global Head of Infectious Diseases Translational Medicine and Research. In September 2008 he moved to Shanghai as VP for Translational Sciences in Asia for Novartis. In September 2010 he joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer, and became CEO in February 2013. He has over 140 authored publications.
Professor Adrian Hill
Professor Adrian Hill is the Director of the Jenner Institute at Oxford University and a Wellcome Trust Senior Investigator, Professor of Human Genetics and a NIHR Senior Investigator. He heads a leading malaria vaccine development programme and also regularly consults on nationally on pandemic threats. His group led the first clinical vaccine trial against the Ebola virus outbreak strain in the major West African emergency in 2014. Professor Hill’s immunogenetics programme focuses on genome-wide and exome-wide association studies of bacterial diseases, particularly tuberculosis and pneumococcal disease, in African and European populations.
Professor of Vaccinology
Professor Sarah Gilbert
Professor Sarah Gilbert is Professor of Vaccinology at Oxford University and the programme director for a Wellcome Trust Strategic Award on Human and Veterinary vaccines at the Jenner Institute. She is a member of the Oxford University Clinical Biomanufacturing Facility management committee, and an acknowledged expert in the preclinical and clinical development of viral vectored vaccines. Professor Gilbert’s chief research interest is the development of vaccines that work by inducing strong and protective T cell responses, in addition to working on the development of the viral vector platform technology and its application in rapid vaccine development for emerging pathogens.
Chief Operating Officer
Chris Ellis obtained both his Registered General Nurse and Registered Mental Nurse qualifications before spending several years working within the National Health Service. Chris left the NHS for clinical research in 1992 and now has over 24 years’ experience in drug development. Chris has worked across all phases of research and has spent time working for Clinical Research Organisations, Site Management Organisations and Biotechnology companies during this time. Chris joined Vaccitech as Clinical Operations Head in August 2016 having previously been Project Lead with responsibility for the lead oncolytic virus programme in a biotechnology company in Oxfordshire.
Chief Business Officer
Graham joins from Agalimmune Limited, a clinical stage Biotech developing directly administered immunotherapies for oncology indications.
As co-founder and Chief Operating Officer, Graham led the licensing, funding and development of a novel cancer immunotherapy and played a lead role in the company’s successful sale to NASDAQ-listed BioLineRx in 2017. Graham qualified as a solicitor in 2005, before moving to co-found technology company MET that was subsequently sold to a group of private investors. He was an investment fund manager at Matrix Securities and for 9 years contributed across the portfolio of life sciences companies within the Animatrix Capital group. Graham’s focus was on developing early stage products and companies targeting the diagnosis and treatment of cancer and infectious diseases. Graham holds a BA Hons degree in Law with French from Newcastle University.
Chief Development Officer
Dr Keith Howard
Dr Keith Howard joined Vaccitech in February 2018 from MedImmune, where he was Senior Director FluMist Manufacturing Science and Technology. After completed his PhD on Leishmania donovani life cycle-related gene expression at the London School of Hygiene and Tropical Medicine, he developed HSV1-based gene therapy vectors for the treatment of neurological disorders and lysosomal storage diseases; firstly at University College London and then at Cantab Pharmaceuticals Ltd in Cambridge. From 2002, he was Head of Vector Development at Oxxon Therapeutics Ltd in Oxford, developing recombinant poxvirus vectors. Subsequently, he was Director of Virology R&D at Baxter Vaccines at Orth an der Donau in Austria, developing vaccines against seasonal and pandemic influenza, chikungunya virus, Ross River virus, SARS coronavirus, and rotavirus. In 2014, Keith transitioned to Pfizer; heading the local MS&T function in analytical and process development work for tick-borne encephalitis and meningitis C vaccines.
Pippa Rathbone is the Executive Administrator for Vaccitech Ltd. Her background is within the executive search and IT industry. Pippa has supported teams in high intensity technology brands such as Microsoft and been part of the Board Management team at Odgers Berndtson, the UK’s largest senior executive and board recruitment business.
Pierre A Morgon
Pierre is CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement. He is also Chairman of the Board of Virometix, as well as Non-Executive Director to the Boards of Theradiag, of Eurocine Vaccines, and of Alma Biotherapeutics.
Pierre has over 30 years of experience in the global life science industry, especially with vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level and as CEO of start-ups. He is a lecturer in several MBA programs in world-class business schools and in life science conferences. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Andrew McLean is the lead life sciences investor for Oxford Sciences Innovation. OSI is a £350 million company investing in the most exciting start-ups built on world-leading Oxford science. Prior to joining OSI Andrew consulted in the pharmaceutical & biotech practice at McKinsey. Andrew is a physician by training, studied philosophy, politics & economics at Christ Church in Oxford and his work background includes stints in wine shops, hospitals & Goldman Sachs.
Adam Stoten is the Chief Operating Officer for Oxford University Innovation Ltd (OUI), the technology transfer company of the University of Oxford, and is responsible for the Licensing & Ventures and Consulting Services activities, in addition to several business support groups. He has worked for more than 15 years in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Prior to his current role Adam led the Life Sciences Licensing & Ventures Group at OUI, where he oversaw the formation of more than 20 new spin out companies. Adam previously worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which raised more than $30M to conduct the first ever efficacy study of a next generation TB vaccine in infants.
Steven Chatfield has spent more than 35 years working in the field of research and development within the Biopharma industry and now works as an independent consultant. His career has focussed on leading the development of new healthcare interventions with a particular emphasis on vaccines and immunotherapy products to combat infectious disease, including experience in the biodefense sector. His previous roles include Executive positions at Medeva plc, Microscience Ltd, and Emergent Biosolutions. Steve also served as an Executive Director of the Health Protection Agency where he was responsible for emergency preparedness and response. He focuses on translational research to drive new technologies and products towards commercialisation through a thorough understanding of the product development process, from research to product launch. Steve holds a PhD in microbiology and has published more than 100 papers in the field of biotechnology.